Collectively, this study demonstrates that bufalin targets GTF3C4 to inhibit the PI3K/AKT pathway and remodels the tumor microenvironment, thereby hindering the malignant progression of breast cancer. This evidence concerns the gene GTF3C4 and breast cancer.